Revive Therapeutics closes first tranche of private placement Jul 15, 2026 06:40PM
Revive Therapeutics Announces Closing of First Tranche of Non-Brokered Private Placement Jul 15, 2026 06:40PM
Revive Therapeutics proposes $1M private placement Jun 26, 2026 04:16PM
Revive Therapeutics Announces Proposed Private Placement Jun 26, 2026 04:15PM
Revive Therapeutics Announces Strategic Expansion of Bucillamine Program Across Infectious Diseases, Defence and Biothreat Medical Countermeasures May 20, 2026 07:45AM


Mar 11, 2026 07:30AM Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases
Mar 3, 2025 08:00AM DiagnaMed Granted FDA Orphan Drug Designation for Molecular Hydrogen to Treat Amyotrophic Lateral Sclerosis